Review Sistematik Temuan Oftalmologi pada Pasien dengan COVID -19: Apa yang Harus Kita Ketahui?
DOI:
https://doi.org/10.36408/mhjcm.v7i1A.463Keywords:
SARS CoV-2, COVID-19, manifestasi okular, konjungtivitis, PCR, swab konungtivaAbstract
Latar belakang: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) merupakan virus penyebab COVID-19 (Corona Virus Disesease-2019) yang pertama kali muncul di Kota Wuhan, Provinsi Hubei, Cina pada akhir Desember 2019. Sejak kemunculannya, SARS COV-2 menunjukkan penambahan jumlah pasien dan kematian yang pesat hingga lintas negara sehingga pada tanggal 11 Maret 2020, WHO (World Health Organization) mengumumkan bahwa COVID-19 dinyatakan sebagai global pandemi. Manifestasi COVID-19 dilaporkan sangat bervariasi, mulai dari gangguan sistem pernafasan, pencernaan, bahkan okular. Namun karena kelangkaan kasus dan situasi pandemi sehingga literatur mengenai manifestasinya pada mata sangat terbatas.
Tujuan: Artikel ini akan menelaah manifestasi klinis SARS-COV-2 pada mata, hubungannya dengan manifestasi sistemik, peran pemeriksaan PCR swab konjungtiva, dan terapi yang diberikan melalui review kualitatif sesuai dengan rekomendasi PRISMA.
Diskusi dan pembahasan masalah: Terdapat 12 dokumen yang ditelaah dalam review ini. Selain gejala pernafasan, COVID-19 juga dilaporkan dapat menyebabkan konjungtivitis dengan ciri umum seperti mata merah, kemosis konjungtiva, mata berair maupun manifestasi okular lain yang lebih jarang. Manifestasi okular dapat sebagai gejala tunggal, prodromal, maupun bersamaan dengan manifestasi sistemik, dan bisa menyebabkan gejala sisa berupa floaters. Terapinya pun bervariasi berdasarkan gejala. Pada kasus COVID-19 dengan konjungtivitis hasil pemeriksaan PCR swab konjungtiva bisa positif maupun negatif.
Kesimpulan: Dapat disimpulkan bahwa manifestasi okular pada pasien COVID-19 mungkin saja terjadi, dan hubungannya dengan manifestasi sistemik sangat bervariasi. Untuk terapi perlu dilakukan penelitian lebih lanjut, dan banyak faktor yang menyebabkan hasil PCR swab konjungtiva tidak sesuai dengan klinis pasien. Sehingga diharapkan agar setiap tenaga kesehatan untuk selalu waspada dan mengambil tindakan pencegahan yang memadai terlepas dari ada atau tidaknya manifestasi okular.
Kata kunci : SARS CoV-2; COVID-19; manifestasi okular; konjungtivitis; PCR; swab konungtiva.
Background: SARS COV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) is a virus that causes COVID-19 (Corona Virus Disesease-2019) which first appeared in Wuhan City, Hubei Province, China at the end of December 2019. Since its emergence, SARS COV-2 showed a rapid enhancement in the number of patients and death cases across countries, because of that, on March 11th, 2020, WHO (World Health Organization) announced that COVID-19 was declared as a global pandemic. The manifestations of COVID-19 were reported to be very varied, ranging from disorders of the respiratory, digestive, and even ocular system. However, due to the scarcity of cases and pandemic situations, the literature of its manifestations in the eyes is very limited.
Objective: This article will review the clinical manifestations of SARS-COV-2 in the eye, their relationship to systemic manifestations, the PCR examination of conjunctival swab’s roles, and therapy provided through qualitative reviews according to PRISMA recommendations.
Discussion: There were 12 documents reviewed in this study. In addition to respiratory symptoms, COVID-19 was also reported to cause conjunctivitis with common features such as red eye, conjunctival chemosis, watery discharge or other ocular manifestations that were less common. Ocular manifestations could be a single symptom, prodromal, or concurrent with systemic manifestations, and could cause sequelae in the form of floaters. Its treatment also varied based on symptoms. In the case of COVID-19 with conjunctivitis the results of conjunctival swab PCR examination could be positive or negative.
Conclusion: It can be concluded that ocular manifestations in COVID-19 patients may occur, and their relationship with systemic manifestations is varies. For therapy, further research is needed, and many factors cause the conjunctival swab PCR results to be incompatible with the patient's clinical course. We hope that every health worker must be aware and take precautions regardless of the presence or absence of ocular manifestations.
Keywords: SARS CoV-2; COVID-19; ocular manifestations; conjunctivitis; PCR; conjunctival swab.
Downloads
References
2. WHO. WHO statement regarding cluster of pneumonia cases in Wuhan, China. Jan 9, 2020. https://www.who.int/china/news/detail/09-01-2020-who-statement-regardingcluster-of-pneumonia-cases-in-wuhan-china (dikutip pada tanggal 4 Juli 2020).
3. Li JO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020; 104(3): 297-8. http://dx.doi.org/10.1136/bjophthalmol-2020-315994
4. WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (dikutip pada tanggal 4 Juli 2020).
5. WHO Emergency Committee. Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (COVID-19). https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) (dikutip pada tanggal 4 Juli 2020).
6. WHO. WHO Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/?gclid=Cj0KCQjw0YD4BRD2ARIsAHwmKVmPoujgOKnenDH-HRtSyG8zUzrgr138UWL0V8niZEmEUdD_cwQj1fwaApPaEALw_wcB (dikutip pada tanggal 12 Juli 2020).
7. WHO. Timeline of WHO’s response to COVID-19 https://www.who.int/news-room/detail/29-06-2020-covidtimeline (dikutip pada tanggal 5 Juli 2020)
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
9. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) affect the eyes? A review of coronaviruses and ocular implications in humans and animals. Ocul Immunol Inflamm. 2020; 28(3):391-5. https://doi.org/10.1080/09273948.2020.1738501
10. Li JO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus Disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020;104(3):297-8. http://dx.doi.org/10.1136/bjophthalmol-2020-315994
11. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China 2019. N Engl J Med. 2020; 382: 727–33. DOI: 10.1056/NEJMoa2001017
12. CDC, WHO Important coronavirus updates for ophthalmologists https://www.aao.org/headline/alert-important-coronavirus-context (dikutip pada tanggal 4 Juli 2020).
13. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
14. Van der Hoek L, Pyrc K, Vermeulen-Oost W, Berkhout RJ, Wolthers KC, et al. Identification of a new human coronavirus. Nat Med. 2004;10(4):368-73. DOI: 10.1038/nm1024
15. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 Infection. J Med Virol. 2020;92(6):589-94. doi:10.1002/jmv.25725
16. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5): 575–8. doi:10.1001/jamaophthalmol.2020.1291
17. Report of the WHO-China joint mission on Coronavirus Disease 2019 vol. 2019. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf (dikutip pada tanggal 4 Juli 2020)
18. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, PRISMA-P Group. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015 Jan 1;4:1.
19. Scalinci SZ, Battagliola ET. Case report conjunctivitis can be the only presenting sign and symptom of COVID-19. IDCases. 2020;1-2. doi.org/10.1016/j.idcr.2020.e00774
20. Navel V, Chiambaretta F, Dutheil F. Haemorrhagic conjunctivitis with pseudomembranous related to SARS-CoV-2. American J Ophthalmol. 2020;19: 100735. doi.org/10.1016/j.ajoc.2020.100735
21. Cheema M, Aghazadeh H, Nazarali S, Ting A, Hodges J, McFarlane A, et al. Keratoconjunctivitis as the initial medical presentation of The Novel Coronavirus Disease 2019 (COVID-19). Canadian Ophthalmol Society. 2020;S0008-4182(20)30305-7. doi.org/10.1016/j.jcjo.2020.03.003
22. Daruich A, Martinc D, Bremond-Gignac D. Ocular manifestation as first sign of Coronavirus Disease 2019 (COVID-19): interest of telemedicine during the pandemic context. J Français d’Ophtalmol. 2020;43(5):389–91. doi.org/10.1016/j.jfo.2020.04.002
23. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; Feb 28; 382:1708-20. doi:10.1056/nejmoa2002032
24. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et.al. Characteristics of ocular findings of patients with Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020;138(5):575-8. doi: 10.1001/jamaophthalmol.2020.1291
25. Hong N, Yu W, Xia J, Shen Y, Yap M, Han W. Evaluation of ocular symptoms and tropism of SARS-Cov-2 in patients confirmed with COVID-19. Acta Ophthalmol. 2020;10.1111/aos.14445. doi: 10.1111/aos.14445
26. Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, et al. The infection evidence of SARS-COV-2 in ocular surface: A single-center cross-sectional study. MedRxiv preprint. 2020. doi.org/10.1101/2020.02.26.20027938
27. Chen L, Deng C, Chen X, Zhang X, Chen B, Yu H, et al. Ocular manifestations and clinical characteristics of 534 cases of COVID-19 in China: A cross-sectional study. MedRxiv preprint. 2020. doi.org/10.1101/2020.03.12.20034678
28. Güemes-Villahoz N, Burgos-Blasco B, Vilela AA, Arriola-Villalobos P, Luna CMR, Sardiña RC, et al. Detecting SARS-CoV-2 RNA in conjunctival secretions: is it a valuable diagnostic method of COVID-19? JMV. 2020;1-6. DOI: 10.1002/jmv.26219
29. Kumar K, Prakash AA, Gangasagara SB, Rathod S, Ravi K, Rangaiah A, et al. Presence of viral RNA of SARS?Cov?2 in conjunctival swab specimens of COVID?19 patients. Indian J Ophthalmol. 2020; 68(6):1015-17. DOI: 10.4103/ijo.IJO_1287_20
30. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2)281-92. doi:10.1016/j.cell. 2020.02.058
31. Yin X, Zhang J. Advance in research of beta coronavirus receptors on ocular surface. Chin J Exp Ophthalmol. 2020;38:254-6. DOI: 10.3760/cma.j.cn115989-20200223-00098
32. Liu Z, Sun CB. Conjunctiva is not a preferred gateway of entry for SARS-Cov-2 to infect respiratory tract. J Med Virol. 2020;1-3. doi:10.1002/jmv.25859
33. Sun CB, Wang YY, Liu GH, Liu Z. Role of the eye in transmitting human coronavirus: what we know and what we do not know. Front Public Health. 2020;8:155. https://doi.org/10.3389/fpubh.2020.00155
34. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631?37. https://doi.org/10.1002/path.1570
35. Liu L, Sun Y, Pan X, Shen W, Liu ZY, Liu YP. Expression of SARS coronavirus s protein functional Receptor?Angiotensin?Converting Enzyme 2 in human cornea and conjunctiva. Chin Ophthal Res. 2004; 22(6):561?4.
36. Sun Y, Liu L, Pan X, Jing M. Mechanism of the action between the SARS?Cov S240 protein and The ACE2 receptor in eyes. Int J Ophthalmol. 2006;6(4):783?6.
37. Lang J, Yang N, Deng J, et al. Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011;6(8):e23710. https://doi.org/10.1371/journal.pone.0023710
38. Lange C, Wolf J, Auw-Haedrich C, Schlecht A, Boneva S, Lapp T, et al. Expression of the COVID-19 receptor ACE2 in the human conjunctiva. J Med Virol. 2020;1-6. doi: 10.1002/jmv.25981
39. Li JO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus Disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol. 2020; 104(3): 297-8. doi: 10.1136/bjophthalmol-2020-315994
40. Yu AY, Tu R, Shao X, Zhou K, Huang J. A comprehensive chinese experience against SARS-Cov-2 in ophthalmology. Eye Vis (Lond). 2020;7:19. doi: 10.1186/s40662-020-00187-2
41. Wei D, Bao L, Xiang Z, Qu Y, Song Z, Gong S. Rhesus macaques can be effectively infected with SARS-CoV-2 via ocular conjunctival route. BioRxiv. 2020. https://doi.org/10.1101/2020.03.13.990036
42. Chan WM, Yuen KSC, Fan DSP, Lam DSC, Chan PKS, Sung JJY. Tears and conjunctival scrapings for coronavirus in patients with SARS. Br J Ophthalmol 2004; 88: 968–9. doi: 10.1136/bjo.2003.039461
43. Lin C, Ye R, Xia YL. A meta-analysis to evaluate the effectiveness of real time PCR for diagnosing novel coronavirus infections. Genet Mol Res. 2015; 14(4): 15634-41. https://doi.org/10.4238/2015
44. Loon S-C, Teoh SCB, Oon LLE, et al. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol 2004; 88: 861–3. doi: 10.1136/bjo.2003.035931
45. Skevaki CL, Galani IE, Pararas MV, Giannopoulou KP, Tsakris A. Treatment of viral conjunctivitis with antiviral drugs. Drugs 2011; 71: 331–47. doi: 10.2165/11585330-000000000-00000
46. Kovalyuk N, Kaiserman I, Mimouni M, et al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: A clinical prospective controlled randomized study. Acta Ophthalmol 2017; 95: e686–92. doi: 10.1111/aos.13416
47. Eggers M, Koburger-Janssen T, Eickmann M, Zorn J. In vitro bactericidal and virucidal efficacy of povidone-iodine gargle/ mouthwash against respiratory and oral tract pathogens. Infect Dis Ther. 2018;7(2):249-259. https://doi.org/10.1007/s40121- 018-0200-7
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2020 Medica Hospitalia : Journal of Clinical Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
